Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application

BACKGROUND: The ICON6 trial (ISRCTN68510403) is a phase III academic-led, international, randomized, three-arm, double-blind, placebo-controlled trial of the addition of cediranib to chemotherapy in recurrent ovarian cancer. It investigated the use of placebo during chemotherapy and maintenance (arm...

Descripción completa

Detalles Bibliográficos
Autores principales: Embleton-Thirsk, Andrew, Deane, Elizabeth, Townsend, Stephen, Farrelly, Laura, Popoola, Babasola, Parker, Judith, Rustin, Gordon, Sydes, Matthew, Parmar, Mahesh, Ledermann, Jonathan, Kaplan, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Data Management and Trial Conduct
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801797/
https://www.ncbi.nlm.nih.gov/pubmed/31347385
http://dx.doi.org/10.1177/1740774519862528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801797/
https://www.ncbi.nlm.nih.gov/pubmed/31347385
http://dx.doi.org/10.1177/1740774519862528

Ejemplares similares